Lunsekimig
Based on 1 Customer Validation
Lunsekimig (SAR443765) is an anti-TSLP/IL13/ALB nonobody composed of 5 sequentially linked variable region heavy chains. Lunsekimig decreases blood eosinophils and lowers plasma levels of IL-5, eotaxin-3, and IgE. Lunsekimig also improves lung function. Lunsekimig can be used for the study and treatment of type 2 inflammatory asthma.
For research use only. We do not sell to patients.
- Purity: 99.00%
- CAS No.: 2770858-49-4
- Molecular Weight:69.702 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
VH-VH-VH-VH-VH
Human
TSLP & IL13 & ALB
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
VH-VH-VH-VH-VH
ELISA, FACS, Functional assay
-
Loaded IL-13 Protein, Human (HEK293, His, HY-P70568) on NTA biosensor, can bind Lunsekimig with an affinity constant of 2.806E-09 M as determined in BLI assay. -
Loaded Serum Albumin/ALB Protein, Human (Biotinylated, HEK293, His-Avi, HY-P78077) on NTA biosensor, can bind Lunsekimig with an affinity constant of 5.297E-08 M as determined in BLI assay. -
Loaded TSLP Protein, Human (HEK293, His, HY-P70818) on HIS1K biosensor, can bind Lunsekimig with an affinity constant of <1.0E-11 M as determined in BLI assay.
Chemical Information
-
CAS No. 2770858-49-4
-
Appearance Liquid
-
Molecular Weight 69.702 kDa
-
Color Colorless to light yellow
-
Synonyms
SAR443765
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (257 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Deiteren A, et al. A first-in-human, single and multiple dose study of lunsekimig, a novel anti-TSLP/anti-IL-13 NANOBODY® compound, in healthy volunteers. Clin Transl Sci. 2024 Jun;17(6):e13864. [Content Brief]
[2]. Kourid MI, et al. Lunsekimig's bispecific targeting of IL-13 and TSLP in asthma: dual targets for synergistic effects? Eur Respir J. 2025 Apr 24;65(4):2500153 [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)